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The binding of leukocytes to intercellular adhesion molecules expressed on 
endothelial surfaces during ischemia and subsequent reperfusion initiates 
leukocyte-mediated r perfusion i jury. Interruption of this leukocyte-endothe- 
lium interaction may therefore prevent reperfusion injury. In an isolated, 
ventilated, blood-perfused rabbit lung preparation, we studied the effect of a 
monoclonal anti-intercellular dhesion molecule antibody on lung function 
during reperfusion. Lungs were harvested with 50 ml/kg cold Euro-Colfins 
flush and 30 /xg prostaglandin E 1 before storage for 18 hours at 4 ° C. 
Experimental groups received low-dose (100 gg) or high-dose (200 /xg) 
anti-intercellular dhesion molecule antibody added to the pulmonary flush at 
harvest and to the initial reperfusate. Eighteen-hour control preparations were 
preserved for 18 hours and received saline solution vehicle. Immediate control 
preparations were harvested and immediately reperfused. The oxygen tension 
in the recirculated pulmonary venous diluent was measured after 30 minutes 
of reperfusion. Histologic specimens were graded by blinded observers for 
degree of leukocyte infiltration (0, normal, to 4, severe infiltration). The mean 
oxygen tensions (---standard error of the mean) were 138.29 - 6.23, 58.86 l_. 
9.14, 86.87 -+ 11.32, and 139.33 - 16.15 mm Hg in immediate control 
preparations, 18-hour control preparations, low-dose antibody group, and 
high-dose antibody group, respectively (p = 0.0001). The leukocyte grades 
(mean --. standard error of the mean) were 1.5 --- 0.723, 3.0 - 0.955, 1.9 - 
0.899, and 1.2 - 0.834, respectively (p = 0.0002). We conclude that anti- 
intercellular adhesion molecule antibody added to the pulmonary flush and 
initial reperfusate r sults in  a dose-dependent enhancement of the reperfused 
lung's ability to oxygenate blood, possibly as a result of decreased leukocyte 
sequestration. (J Thorac Cardiovasc Surg 1996;111:941-7) 
T he sequestration of activated leukocytes within pulmonary allografts has been established as a 
significant cause of pulmonary reperfusion injury 
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after lung transplantationJ Correspondingly, leuko- 
cyte depletion of the recipient by means of filtration 
methods has been shown to attenuate reperfusion 
injury in experimental models. 2' 3 Practical difficul- 
ties with effective leukocyte filtration and concerns 
about leukopenia in already immunocompromised 
patients, however, have prevented the routine clin- 
ical application of leukocyte depletion in lung trans- 
plant centers. 1'4 Newer methods of limiting leuko- 
cyte-mediated reperfusion injury that exploit our 
growing understanding of the molecular mecha- 
nisms of the leukocyte-endothelium interaction dur- 
ing reperfusion have been proposed. For example, 
the leukocyte membrane glycoprotein CD18 binds 
to the endothelium-based intercellular adhesion 
molecule-1 (ICAM-1), initiating leukocyte demar- 
gination early in reperfusion. 5' 6 Monoclonal anti- 
bodies have been developed that bind to the 
ICAM-1 receptor and prevent this interaction. 7-9 
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We hypothesized that the administrat ion of an 
ant i - ICAM-1  monoclonal  ant ibody to pulmonary 
allografts before reperfusion would decrease leuko- 
cyte sequestrat ion and thus attenuate reperfusion 
injury. 
Materials and methods 
We developed a model of isolated, ventilated, and 
blood-perfused rabbit lung function, which was employed 
in this protocol. All animals received humane care in 
compliance with the "Principles of Laboratory Animal 
Care" formulated by the National Society for Medical 
Research and the "Guide for the Care and Use of 
Laboratory Animals" prepared by the Institute of Labo- 
ratory Animal Resources and published by the National 
Institute of Health (NIH Publication No. 86-23, revised 
1985). 
Harvest procedure. Forty New Zealand White rabbits 
weighing 3.0 to 3.5 kg were used as lung donors. Each 
animal was anesthetized with intramuscular ketamine (50 
mg/kg) and xylazine (5 mg/kg). A tracheostomy was 
performed and mechanical ventilation was instituted with 
a constant-pressure ventilator (RSP1002; Kent Scientific 
Corporation, Litchfield, Conn.) on room air and a rate of 
20 breaths/min. A median sternotomy was then performed 
and thymectomy was carried out. The two superior venae 
cavae and one inferior vena cava were loosely encircled 
with ligatures, and the pericardium was opened. Both the 
pulmonary artery (PA) and the aorta were dissected free 
and similarly encircled. A purse-string suture was then 
placed in the free wall of the right ventricle, and the rabbit 
was heparinized (500 U/kg). After injection of 30 /xg 
prostaglandin E 1 into the PA, the venae cavae were 
interrupted and the onset of ischemia was noted. The PA 
was then cannulated through the right ventricular purse- 
string, and both the right ventricular and PA ligatures 
were tied around the cannula. After venting of the left 
ventricle and ligation of the aorta, 50 mg/kg of saline 
solution at 4 ° C was infused into the PA from a height of 
30 cm. Topical cooling was achieved with cold saline 
solution slush. During PA flush, the left atrium was 
cannulated through a left ventricular purse-string. After 
completion of the PA flush, the inflow and outflow 
cannulas were clamped. Care was taken to leave the 
pleurae intact until the completion of the flush to avoid 
parenchymal injury. The tracheostomy tube was then 
clamped at end-inspiration and the heart-lung block was 
excised. The lungs were stored at 4 ° C in saline solution. 
Reperfusion procedure. Forty-five heparinized and 
anesthetized New Zealand White rabbits erved as venous 
blood donors. Saline solution was added to each aliquot of 
blood to achieve a hematocrit of 28% to 30%. During 
reperfusion, the lungs were suspended by a force trans- 
ducer in a warmed, humidified chamber. Room air venti- 
lation at 20 breaths/min was reestablished with a constant- 
pressure ventilator. The initial maximum inspiratory 
pressure was set to achieve a tidal volume of 10 ml/kg of 
donor rabbit weight and was subsequently held constant. 
Any lung with evidence of air leakage was excluded. The 
inflow and outflow cannulas were then connected to a 
venous blood-filled perfusion circuit, with care taken to 
avoid the introduction of air bubbles. The circuit (Kent 
Scientific Corporation) was designed to recirculate 200 ml 
warmed blood with a roller pump (7521-40; Coie-Parmer 
Instrument Company, Niles, Ill.) and a blood filter 
(2C7600; Baxter Healthcare Corp., Deerfield, Ill.) at a 
rate of 40 ml/min. Continuous recording of PA pressure, 
pulmonary venous pressure, lung weight, airway flow, and 
airway pressure was carried out with a dynamic data- 
acquisition program (Workbench PC; Strawberry Tree, 
Inc., Sunnydale, Calif.) run on a personal computer 
(470A; Compaq Prolinea, Houston, Texas). This program 
allowed immediate calculation of tidal volume, pulmonary 
vascular resistance (Pulmonary vascular resistance = 80 × 
[PA pressure - Pulmonary venous pressure]/Flow), and 
dynamic airway compliance (Dynamic airway compliance 
= Tidal volume/Airway pressure). The pulmonary venous 
pressure was maintained between 5 and 8 mm Hg by 
changing the height of an outflow reservoir in the circuit. 
Pulmonary venous blood samples were collected for blood 
gas analysis (Corning 178 pH/Blood Gas Analyzer; Corn- 
ing Inc., Coming, N.Y.) at 1, 10, 20, and 30 minutes after 
the start of reperfusion. Oxygen contact with exposed 
blood surfaces inside reservoir containers was minimized 
by the continuous passive infusion of 100% nitrogen. 
Experimental protocol. Ten double-lung blocks were 
reperfused immediately after harvest, serving as immedi- 
ate control (IC) preparations. For our ischemic groups, we 
chose a storage interval of 18 hours, after a series of 
preliminary experiments in which 24 hours of cold storage 
was associated with a rapid hemorrhagic demise of the 
lung before completion of 30 minutes of reperfusion. By 
contrast, 6- and 12-hour ischemic intervals produced little 
measurable lung injury. Ten lungs were stored for 18 
hours at 4°C and then reperfused, serving as 18-hour 
control preparations. Two treatment groups were simi- 
larly harvested and stored at 4°c  for 18 hours but 
received low- or high-dose antibody therapy, respectively. 
Ten lungs in the low-dose group received 100/xg purified 
anti-ICAM-1 monoclonal antibody (RR1; Boehringer 
Ingelheim Corp., Ridgefield, Conn.) administered intra- 
vascularly with the last 20 ml of Euro-Collins flush during 
harvest and a second 100 /xg dose intravascularly in the 
initial reperfusate. Ten lungs in the high-dose group 
received 200/xg anti-ICAM-1 antibody administered in a 
similar manner, both during harvest and again before 
reperfusion. All lungs were reperfused for 30 minutes. 
At the completion of the study, samples of the left lower 
lobe were weighed and dried for calculation of wet-to-dry 
weight ratios. Histologic specimens were taken from the 
right lower lobe and placed in formalin. The histol0gic 
specimens were graded for the degree of leukocyte se- 
guestration by three blinded observers according to a 
5-point scale modified from the method of Yousem and 
coworkers, m The grading classification is outlined in 
Table I. 
Statistical analysis. Statistical analysis was performed 
for the four groups by means of analysis of variance on the 
software STATISTICA (StatSoft, Inc., Tulsa, Okla.). Sig- 
nificant differences were determined by means of Tukey's 
Honestly Significant Difference test. The data are re- 
ported as mean -+ standard error of the mean. 
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Table I. Grading of leukocyte sequestration 
Grade Description 
0 No evidence of leukocyte sequestration; ormal ung 
1 Less than 25% of interstitium infiltrated by leukocytes 
2 50% of interstitium infiltrated by leuk0cytes 
3 75% of interstitium infiltrated by leukocytes 
4 100% of interstitium infiltrated by leukocytes 
Results 
The capacity of the room air-ventilated lungs to 
oxygenate blood at the completion of the 30-minute 
period of reperfusion revealed an expected impair- 
ment in 18-hour control lungs compared with the IC 
group. Administration of anti-ICAM-1 monoclona! 
antibody markedly enhanced the oxygenation capac- 
ity in a dose-dependent manner (Fig. 1). By contrast 
to the IC and 18-hour control groups, the lungs 
receiving low- and high-dose anti-ICAM-1 antibody 
were capable of generating oxygen tensions of 
86.87 +_ 11.32 and 139.33 _+ 16.15, respectively (p = 
0.0001). The degree of leukocyte sequestration was 
also increased in the 18-hour control group com- 
pared with the IC group. Administration of anti- 
ICAM-1 antibody was associated with decreased 
histologic evidence of leukocyte sequestration, again 
in a dose-dependent manner (Fig. 2). The leukocyte 
grade (mean _+ standard error of the mean) was 1.5 
_+ 0.723 in the IC group versus 3.0 _+ 0.955 in the 18 
hour-stored lung group. In lungs receiving antibody, 
the mean leukocyte grade was improved at 1.9 _+ 
0.899 in the low-dose group and 1.2 +_ 0.834 in the 
high-dose group (p = 0.0002). Representative his- 
tologic specimens taken from each cohort of reper- 
fused lungs revealed a marked reduction in leuko- 
cyte sequestration associated with the administration 
of blocking antibody (Fig. 3). Measures of PA pres- 
sure, pulmonary vascular resistance, airway compli- 
ance, lung weight, and wet-to-dry weight ratios were 
not improved by the administration f anti-ICAM-1 
antibody. These data are presented in Table II. 
Discussion 
The complex molecular events that orchestrate 
adhesion between leukocytes and vascular endothe- 
lium during inflammatory esponses have been well 
characterized.5, 6 Leukocyte adhesion to endothelial 
cells is mediated by a group of glycoproteins ex- 
pressed on the surface of leukocytes known as /32 
integrins. Each integrin is comprised of a common 
/3-subunit (CD18) bound to one of 3 a-subunits 











Immediate Control 18 Hr Control 18 Hr Low Dose 18 Hr High Dose 
Cohort 
Fig. 1. Oxygenation capacity (partial pressure of oxygen 
in millimeters of mercury) after 30 minutes of reperfusion. 
p = 0.0001 for 18-hour control group versus low-dose 
group, 18-hour control group versus high-dose group, 
low-dose versus high-dose group, and IC group versus 
18-hour control group. 
heterodimers: CDlla/CD18, CDllb/CD18, and 
CD11c/CD18. 7 The CDlla/CD18 and CDllb/CD18 
molecules bind to an endothelium-based receptor 
called ICAM-1, initiating the process of leukocyte 
demargination. Various proinflammatory mediators 
such as interleukin-1 and tumor necrosis factor 
released in response to ischemia both increase the 
expression of these adhesion molecules and enhance 
their binding effectiveness, ' 11 Reperfusion of the 
ischemic pulmonary vasculature with whole blood is 
therefore associated with a profound sequestration 
of leukocytes within the allograft. Subsequent al- 
lograft damage caused by leukocyte-generated reac- 
tive oxygen species and proteolytic enzymes 11-14 can 
result in acute lung dysfunction after transplanta- 
tion. 
Because the adhesion of activated leukocytes to 
damaged endothelium is thought to be an early and 
pivotal event in the pathophysiology of reperfusion 
injury after ischemia, a number of investigators have 
tried to reduce solid organ reperfusion injury by 
blocking this initial leukocyte-endothelium interac- 
tion. Antibodies directed against the leukocyte 
CD18 complex (anti-CD18) 15 and against the endo- 
thelial ICAM-1 receptor (anti-ICAM-1) 16 have 
been shown to minimize neurologic deficits during 
reperfusion after ischemia of the rabbit central 
nervous system. Anti-ICAM-1 therapy has been 
shown to be protective in a model of kidney isch- 
emia-reperfusion. 17 Leukocyte antiadhesion therapy 
also appears to limit the size of myocardial infarc- 
tion, Is minimize the severity of systemic inflamma- 
tion after cardiopulmonary bypass, 19' zo and prevent 
9 4 4 Buchanan et al. 







Immediate Control 18 Hr Control 18 Hr Low Dose 18 Hr High Dose 
Cohori 
Fig. 2. Degree of leukocyte sequestration after 30 min- 
utes of reperfusion, p = 0.0002 for 18-hour control group 
versus low-dose group, 18-hour control group versus 
high-dose group, and IC group versus 18-hour control 
group. 
myocardial stunning, low reflow, and edema forma- 
tion after experimental heart transplantation. 21 
Evidence that preventing leukocyte adhesion 
within the pulmonary capillary bed protects the lung 
from the effects of ischemia nd reperfusion has also 
been reported. Schueler and coworkers 3 demon- 
strated that leukocyte depletion in a porcine model 
of double-lung transplantation improves the isch- 
emic tolerance of the lung, with excellent lung 
function noted after 24 hours of Preservation. 
Kapelanski and colleagues 7 reported that an anti- 
CD18 monoclonal antibody was capable of improv- 
ing gas exchange and decreasing lung water accu- 
mulation after 4 hours of preservation and 6 hours 
of reperfusion in a model of canine single-lung 
transplantation. I terestingly, other features of lung 
reperfusion injury, including pulmonary hyperten- 
sion, increased pulmonary vascular esistance, and 
reduced airway compliance, were not improved with 
the antibody. Horgan and colleagues 8' 9 carried out 
experiments in which 24 hours of in situ rabbit lung 
ischemia was followed by 2 hours of reperfusion. 
They showed, with antibodies directed against both 
CD18 and ICAM-1, that neutrophil sequestration 
within the pulmonary vascular microcirculation is
enhanced by upregulation of the ICAM-1 receptor 
during ischemia nd is a major determinant of lung 
reperfusion injury. Measures of oxygenation capac- 
ity, pulmonary vascular hemodynamics, and airway 
compliance during reperfusion i  these experiments 
were not recorded. 
To further evaluate the role of leukocytes in 
mediating lung reperfusion injury and to deter- 
mine whether antagonism of the ICAM-1 receptor 
could ameliorate the effects of this injury, we 
employed an isolated, ventilated, blood-perfused 
model of rabbit lung function with which we have 
experience. With RR1, a monoclonal anti- 
ICAM-1 antibody, we were able to demonstrate a 
dose-dependent enhancement in rabbit lung oxy- 
genation capacity after 18 hours of cold preserva- 
tion and 30 minutes of reperfusion. This improved 
oxygenation correlated with decreased leukocyte 
sequestration. Similar to the results of Kapelanski 
and associates, 7 we were unable to achieve im- 
provements in reperfusion-associated pulmonary 
hypertension or reduced airway compliance. 
These features of reperfusion injury in the lung 
may be mediated either wholly or in part 
by leukocyte-independent or ICAM-l-indepen- 
dent mechanisms. 
All of the lungs subjected to 18 hours of ischemia, 
regardless of anti-ICAM-1 therapy, accumulated 
lung water, as measured by increased lung weight 
during reperfusion and by increased wet-to-dry 
weight ratios at the completion of reperfusion. 
These findings suggest that the frequently observed 
capillary leakage phenomenon can occur without 
significant infiltration of leukocytes in this model 
and that measures designed to prevent leakage may 
need to be more broadly focused than any specific 
antileukocyte therapy. Because the administration 
of an isotype-matched control monoclonal antibody 
directed against an adhesion-independent l ukocyte 
antigenic determinant was not used, we cannot 
exclude the remote possibility that nonspecific ef- 
fects of monoclonal antibody administration con- 
tributed to our results. 
Although the safety and efficacy of anti-ICAM-1 
monoclona! antibody in human beings has yet to be 
firmly established, a phase I trial of its use as an 
immunosuppressant in renal allograft recipients has 
found no significant adverse side effects. 22 A second 
published trial of anti-ICAM-1 therapy as an anti- 
inflammatory agent i  patients with rheumatoid 
arthritis has further substantiated the drug's safety, 
with reported clinical improvement lasting as long as 
55 days after completion of a 5-day course of 
anti-ICAM-1 therapy, a3 
In conclusion, the administration of a monoclonal 
anti-ICAM-1 antibody prevented the impairment of 
oxygenation capacity and was capable of reducing 
leukocyte infiltration in this model of isolated lung 
function. These data provide additional evidence of 
the detrimental effect of leukocytes during pulmo- 
nary reperfusion after ischemia. Further, these data 
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Fig. 3. Histologic specimens (Hematoxylin-eosin stain; original magnification × 125). A, Reperfused 
immediately after harvest (IC group). Minimal interstitial infiltration with inflammatory cells. Normal 
architecture preserved. B, Reperfused after 18 hours of cold ischemia (18-hour control group). Severe 
infiltration with polymorphonuclear cells and erythrocytes with distortion of the microscopic archi- 
tecture. C, Low-dose antibody and 18 hours of cold ischemia (low-dose group). Moderate infiltrate 
with polymorphonuclear cells and well-preserved architecture. D, High-dose antibody and 18 hours of 
cold ischemia (high-dose group). No interstitial infiltrate with inflammatory cells. Architecture well 
preserved. 
Table II. Parameters unaffected by administration of a ti-ICAM-1 antibody 
PA pressure PVR Airway compliance Lung weight Wet-to-dry 
(ram Hg) (dynes" sec/cm -4 ) (% change) (% change) weight ratio 
IC  21.37 -+ 1.91 55.18 -+ 5.45 3.92 -+ 8.26 15.93 + 8.27 4.65 -+ 0.72 
18-hour  contro l  46.69 _+ 9.20 87.90 -+ 18.37 -26 .73  _+ 7.28 103.13 + 29.92 7.30 _+ 0.69 
18-hour  low-dose group 43.34 _+ 7.38 82.75 _+ 14.47 39.04 _+ 5.89 136.67 + 26.95 6.74 _+ 0.95 
18-hour  high-dose group 36.26 _+ 4.63 69.66 + 9.54 -23 .74  _+ 8.41 93.18 _+ 17.90 7.79 -+ 1.21 
p 0.0396; IC  vs NS 0.0024; IC vs 0.0044; IC  vs NS 
18-hour  contro l  18-hour  contro l  18-hour  control  
and IC vs 18-hour  and  IC vs 18-hour  
low-dose group low-dose group 
Data listed represent mean values -+ standard error of the mean recorded at the end of a 30-minute period of reperfusion. PVR, Pulmonary vascular 
resistance; NS, not significant. 
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support  the impor tance  of the endothel ia l  ICAM-1  
receptor  in mediat ing  leukocyte sequestrat ion in 
reper fus ion- in jured lungs. 
We express our appreciation to Mr. Anthony Herring 
for his invaluable technical assistance. 
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Discussion 
Dr. Margaret D. Allen (Seattle, Wash.). This is certainly 
an elegant study in an ex vivo model of clinical reperfusion 
injury after lung transplantation, which certainly is a 
major clinical problem. I appreciate that this is a very 
difficult and sophisticated model. I do have a few ques- 
tions. 
First, as you know, many lung operations do not require 
bypass, and bypass circuitry in your experiment itself could 
potentially result in upregulation of cytokines, adhesion 
molecules, and other factors. To what extent could this 
have influenced your results, either pro or con? 
Dr. Buehanan. There is plastic tubing to which the 
blood is exposed in our circuit. This blood is passed 
through a filter. Our leukocytes are undoubtedly acti- 
vated, and our adhesion receptors are potentially upregu- 
late& Our system--like any isolated experimental prepa- 
ra t ion -may introduce some other variables. 
Dr. Allen. Second, the monoclonal antibody RR1 that 
you used binds only to the first and second domains of 
ICAM-1 and thus blocks the LFA-1 binding site but not 
the Mac-1 binding site, which is the most important for 
neutrophils. There are other anti-ICAM-1 antibodies that 
do block both. Could this possibly explain why you saw 
improvement in some parameters but not in others? Did 
you look at what leukocyte subpopulations were present? 
For instance, were macrophages present, or were you 
selecting out certain populations? 
Dr. Buchanan. The RR1 antibody we used is known to 
be extremely specific, and in fact I believe this explains our 
lack of improvement in hemodynamics and airway func- 
tion. I think you are right. If we looked at subpopulations 
of cells involved or the particular type of ICAM receptor 
involved, we would see that only a subset was blocked by 
our experiment. 
Dr. Allen. Finally, I noticed that you did not use an 
isotype-matched antibody in your control preparations, 
and I was just wondering about your thoughts on this. 
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Dr. Buchanan. I am not convinced of the utility of 
isotype-matched antibody in this preparation. 
Dr. Allen. It would be a nonfunctional ntibody to 
control for binding to FC receptors. 
Dr. Buchanan. We did not use such an antibody in this 
experiment, but perhaps itwould be interesting todo so in 
the future. 
Dr. Allen. I think that the approach you describe would 
certainly have potential for clinical application. 
Dr. Alden H. Harken (Denver, Colo.). I compliment you 
for initiating a discussion that I think is going to be a 
theme of today's program. We have several papers on the 
program that allude to the fact that all cardiac surgeons 
place patients on cardiopulmonary bypass, and if we leave 
them there for an hour we can culture bacteria from our 
cardiopulmonary bypass olution. Whether or not we like 
to acknowledge that, we are then elaborating orprovoking 
endotoxemia, which then may elaborate tumor necrosis 
factor, with or without complement, and then express the 
CD-11 and CD-18 neutrophil receptors and upregulate 
the ICAM on our endothelial cells, blowing holes in 
endothelial cells and transudating fluid and albumin into 
the lungs. Whether we acknowledge that or not, it hap- 
pens in all of our patients, sometimes subclinically and 
sometimes not. I have two interrelated questions. One is 
related to your model. As I look at your data, and I agree 
with your interpretation completely, in your high- and 
low-dose antibody systems I wanted to see a relationship 
between the adherence ofneutrophils tothose endothelial 
ceils and oxygenation. I saw no difference with the high- 
and low-close antibody relative to neutrophils but I did see 
a significant improvement in oxygenation, and that relates 
to my second question. If you can break this sequence, 
which you and I both want to do, why have all the clinical 
studies looking at multiple organ failure or whatever 
parameter you want against antiendotoxin, anti-tumor 
necrosis factor, or anti-ICAM-1 been failures? I would 
like your interpretation f these observations. 
Dr. Buchanan. I will approach the second observation 
first. I suspect the problems that we are seeing after bypass 
in endotoxic shock are multifactorial, and each of the 
interventions--the us of an antibody to ICAM, the use of 
an antibody to endotoxin--by contrast is extremely spe- 
cific. Perhaps we need to combine these modalities to see 
some more clinically relevant response. 
Regarding your first point, I think that one of the 
important techniques we need to develop in the labora- 
tory, and we are in the process of doing just that, is 
figuring out a way to actually look at the leukocyte binding 
to the endothelium, for example by means of an immu- 
nohistochemical technique. It would be interesting ti~ see 
the exact numbers of leukocytes that are binding, where 
they are binding, and if in fact they are binding to the 
ICAM-1 receptor. We really do not know that. 
Dr. David A. Fullerton (Denver, Colo.). I too congratu- 
late you on a very pretty study, and I also think it is 
clinically relevant, which adds to its value. I have a couple 
of questions. 
First, our interest has been in the vascular component 
of reperfusion i jury, and I was curious as to whether you 
had the opportunity to discern whether your antibody 
might preserve vascular function after reperfusion. 
Dr. Buchanan. We did not look at that in this particular 
experiment. I  would certainly be interesting, for example, 
to take rings from our lungs and put them on a constric- 
tion apparatus to see whether the ability for endothelium- 
dependent relaxation was preserved. We are in the pro- 
cess of carrying out some such experiments now. 
Dr. Fullerton. In addition, 18 hours of ischemia is of 
course a fairly large insult, and I was curious as to whether 
you have tried shorter periods of ischemia. If so, are those 
results substantially different from these, or did you 
choose 18 hours for some methodologic reason? 
Dr. Buchanan. Preliminary data suggested that these 
rabbit lungs are quite sensitive to ischemia, with a 
24-hour period of ischemia resulting in many of the 
lungs simply crashing and not surviving even the 30- 
minute period of reperfusion. By contrast, after just 
2 or 4 hours of ischemia, lungs studied reveal little 
evidence of reperfusion i jury. In an effort to unmask a
significant but treatable injury, we settled on 18 hours. 
Dr. Fullerton. Finally, is it necessary to provide the 
antibody both at the end of your flush and on reperfusion, 
or is it sufficient to provide it simply on reperfusion? 
Dr. Buchanan. I cannot answer that from our data, but 
I would guess that if I had to administer antibody at one 
point or the other I would choose to do so just before 
reperfusion. Theoretically, these ICAM receptors are not 
significantly upregulated immediately after harvest or 
during the flush. Time is required for messenger RNA to 
be produced and translated to actually result in upregu- 
lation of the receptor. 
